PubRank

Walter N Hittelman

Author PubWeight™ 52.63‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Role for the BRCA1 C-terminal repeats (BRCT) protein 53BP1 in maintaining genomic stability. J Biol Chem 2003 2.03
2 Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res 2005 2.01
3 Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst 2003 1.75
4 ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res 2006 1.66
5 Rad17 phosphorylation is required for claspin recruitment and Chk1 activation in response to replication stress. Mol Cell 2006 1.65
6 Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 2006 1.55
7 Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol Cancer Ther 2006 1.41
8 Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 2006 1.33
9 Disruption of the Rad9/Rad1/Hus1 (9-1-1) complex leads to checkpoint signaling and replication defects. Oncogene 2004 1.20
10 Cancer stem cells and tumor response to therapy: current problems and future prospects. Semin Radiat Oncol 2009 1.13
11 The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment. J Invest Dermatol 2012 1.07
12 hSnm1 colocalizes and physically associates with 53BP1 before and after DNA damage. Mol Cell Biol 2002 1.07
13 Oleandrin-mediated oxidative stress in human melanoma cells. J Exp Ther Oncol 2006 1.07
14 Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res 2006 1.06
15 Promyelocytic leukemia protein sensitizes tumor necrosis factor alpha-induced apoptosis by inhibiting the NF-kappaB survival pathway. J Biol Chem 2003 1.05
16 Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells. Mol Cancer Ther 2011 1.04
17 Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. J Clin Oncol 2007 1.03
18 Sensing of blood pressure increase by transient receptor potential vanilloid 1 receptors on baroreceptors. J Pharmacol Exp Ther 2009 1.02
19 Targeted delivery of human pro-apoptotic enzymes to tumor cells: In vitro studies describing a novel class of recombinant highly cytotoxic agents. Mol Cancer Ther 2003 1.01
20 The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA. Mol Cancer Ther 2007 1.01
21 Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst 2003 1.00
22 Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. Oncogene 2003 0.99
23 Imaging and analysis of 3D tumor spheroids enriched for a cancer stem cell phenotype. J Biomol Screen 2010 0.96
24 T-cell-specific deletion of Mof blocks their differentiation and results in genomic instability in mice. Mutagenesis 2013 0.96
25 Multiplexed in situ immunofluorescence using dynamic DNA complexes. Angew Chem Int Ed Engl 2012 0.95
26 Configuring robust DNA strand displacement reactions for in situ molecular analyses. Nucleic Acids Res 2011 0.91
27 Multiplexed and reiterative fluorescence labeling via DNA circuitry. Bioconjug Chem 2010 0.90
28 RING finger and WD repeat domain 3 (RFWD3) associates with replication protein A (RPA) and facilitates RPA-mediated DNA damage response. J Biol Chem 2011 0.90
29 Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors. Cancer Res 2013 0.89
30 Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system. Anesth Analg 2012 0.89
31 Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin Cancer Res 2002 0.89
32 Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Mol Cancer Ther 2011 0.89
33 Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila) 2009 0.87
34 Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark 2007 0.87
35 AURKA amplification, chromosome instability, and centrosome abnormality in human pancreatic carcinoma cells. Cancer Genet Cytogenet 2005 0.87
36 Kub5-Hera, the human Rtt103 homolog, plays dual functional roles in transcription termination and DNA repair. Nucleic Acids Res 2014 0.85
37 Characterization and mechanistic studies of a novel melanoma-targeting construct containing IκBa for specific inhibition of nuclear factor-κB activity. Neoplasia 2010 0.81
38 Prevention of bronchial hyperplasia by EGFR pathway inhibitors in an organotypic culture model. Cancer Prev Res (Phila) 2011 0.81
39 Impact of cyclin D1 A870G polymorphism in esophageal adenocarcinoma tumorigenesis. Semin Oncol 2005 0.81
40 Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2. BMC Cancer 2011 0.80
41 Molecular mechanisms in Barrett's metaplasia and its progression. Semin Oncol 2007 0.79
42 A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamous cell carcinoma. Radiother Oncol 2002 0.78
43 Bax345/BLyS: a novel, completely human fusion protein targeting malignant B cells and delivering a unique mitochondrial toxin. Cancer Lett 2012 0.78
44 Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu. Mol Cancer Ther 2013 0.78
45 The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma. Biochem Pharmacol 2012 0.78
46 Biologic correlates of a biochemoprevention trial in advanced upper aerodigestive tract premalignant lesions. Cancer Epidemiol Biomarkers Prev 2002 0.77
47 Enhanced response to C225 of A431 tumor xenografts growing in irradiated tumor bed. Radiother Oncol 2009 0.77
48 Quantitative histopathology and chromosome 9 polysomy in a clinical trial of 4-HPR. Gynecol Oncol 2004 0.77
49 Programming in situ immunofluorescence intensities through interchangeable reactions of dynamic DNA complexes. Chembiochem 2012 0.77
50 The functionalized human serine protease granzyme B/VEGF₁₂₁ targets tumor vasculature and ablates tumor growth. Mol Cancer Ther 2013 0.76
51 Deficiency of cell cycle checkpoints and DNA repair system predispose individuals to esophageal cancer. Mutat Res 2006 0.76
52 Evaluating quality in clinical cancer research: the M.D. Anderson Cancer Center experience. Oncology 2009 0.75
53 Improvement and application of fluorescence inter-simple sequence repeat polymerase chain reaction for the study of subclonal growths in lung epithelial cell populations. Chest 2004 0.75
54 Cervical chromosome 9 polysomy: validation and use as a surrogate endpoint biomarker in a 4-HPR chemoprevention trial. Gynecol Oncol 2005 0.75